UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

The New England journal of medicine, 2021-04, Vol.384 (16), p.1529-1541

2021

Volltextzugriff (PDF)

No "One Size Fits All" Approach Exists

Oncology (Williston Park, N.Y.), 2019-01, Vol.33 (1), p.21

Zelnak, Amelia B

2019

Volltextzugriff (PDF)

Special Considerations in Early-stage Breast Cancer Patients and Survivors

Obstetrics and gynecology clinics of North America, 2013-09, Vol.40 (3), p.573-582

Zelnak, Amelia B., MD, MSc

2013

Volltextzugriff (PDF)

Optimizing Endocrine Therapy for Breast Cancer

Journal of the National Comprehensive Cancer Network, 2015-08, Vol.13 (8), p.e56-e64

2015

Volltextzugriff (PDF)

Management of patients with HER2‐positive metastatic breast cancer: Is there an optimal sequence of HER2‐directed approaches?

Cancer, 2015-01, Vol.121 (1), p.17-24

2015

Volltextzugriff (PDF)

Clinical pharmacology and use of microtubule-targeting agents in cancer therapy

Methods in molecular medicine, 2007, Vol.137, p.209

Zelnak, Amelia B

2007

Volltextzugriff (PDF)

The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients

Annals of surgical oncology, 2015-04, Vol.22 (4), p.1088-1094

2015

Volltextzugriff (PDF)

Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy

International Journal of Breast Cancer, 2015-01, Vol.2015 (2015), p.1-7

2015

Volltextzugriff (PDF)

High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer to a Novel Nonanthracycline Neoadjuvant Chemotherapy

Clinical breast cancer, 2015-02, Vol.15 (1), p.31-36

2015

Volltextzugriff (PDF)

Genomic subtypes in choosing adjuvant therapy for breast cancer

Oncology (Williston Park, N.Y.), 2013-03, Vol.27 (3), p.204-210

2013

Volltextzugriff (PDF)

Final Results from Phase II Trial of Neoadjuvant Docetaxel and Capecitabine Given Sequentially or Concurrently for HER2-Negative Breast Cancers

Clinical breast cancer, 2013-06, Vol.13 (3), p.173-179

2013

Volltextzugriff (PDF)

Targeting angiogenesis in advanced breast cancer

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2007-01, Vol.21 (4), p.209-214

2007

Volltextzugriff (PDF)

Adjuvant Hormonal Therapy for Early-Stage Breast Cancer

Advances in Breast Cancer Management, Second Edition, 2008, Vol.141, p.63-78

2008

Volltextzugriff (PDF)

JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS2660-TPS2660

2019

Volltextzugriff (PDF)

Abstract OT2-16-01: ONCX-NAV-G201: A phase 2, basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors: Triple-negative breast cancer cohort (trial in progress)

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.OT2-16-01-OT2-16-01

2023

Volltextzugriff (PDF)

Chemoprevention of breast cancer

Current problems in cancer, 2004-07, Vol.28 (4), p.201-217

2004

Volltextzugriff (PDF)

Hormonal Therapy for Cancer

The American Cancer Society's Principles of Oncology, 2018, p.236-243

2018

Volltextzugriff (PDF)

Targeted Therapy for Metastatic Breast Cancer

Emerging Cancer Therapeutics, 2010, Vol.1 (3), p.565-576

2010

Volltextzugriff (PDF)

Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.1016-1016

2019

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(18)
Buchkapitel
(2)

Sprache

Englisch
(20)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Humans
(12)
Female
(11)
Oncology
(11)
Breast Cancer
(9)
Breast Neoplasms - Drug Therapy
(7)
Breast Neoplasms - Metabolism
(5)
Breast Neoplasms - Pathology
(5)
Neoplasm Staging
(5)
Adult
(4)
Antineoplastic Agents - Therapeutic Use
(4)
Middle Aged
(4)
Aged
(3)
Antineoplastic Agents - Pharmacology
(3)
Cancer
(3)
Chemotherapy, Adjuvant
(3)
Clinical Trials As Topic
(3)
Obstetrics And Gynecology
(3)
Receptor, Erbb-2 - Metabolism
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

No "One Size Fits All" Approach Exists

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial

Special Considerations in Early-stage Breast Cancer Patients and Survivors

Optimizing Endocrine Therapy for Breast Cancer

Management of patients with HER2‐positive metastatic breast cancer: Is there an optimal sequence of HER2‐directed approaches?

Clinical pharmacology and use of microtubule-targeting agents in cancer therapy

The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients

Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy

High Pathologic Complete Response in Her2-Positive, Early-Stage Breast Cancer to a Novel Nonanthracycline Neoadjuvant Chemotherapy

Genomic subtypes in choosing adjuvant therapy for breast cancer

Final Results from Phase II Trial of Neoadjuvant Docetaxel and Capecitabine Given Sequentially or Concurrently for HER2-Negative Breast Cancers

Targeting angiogenesis in advanced breast cancer

Adjuvant Hormonal Therapy for Early-Stage Breast Cancer

JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect

Abstract OT2-16-01: ONCX-NAV-G201: A phase 2, basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors: Triple-negative breast cancer cohort (trial in progress)

Chemoprevention of breast cancer

Hormonal Therapy for Cancer

Targeted Therapy for Metastatic Breast Cancer

Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results

Suchergebnisse filtern